People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Biotechnology, Other, Business Services, Other Technology, Investment Vehicle
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | — | Biotechnology | Series B | $61.3M | $5.2M | 2024 |
| NexImmune, Inc. | — | Biotechnology | Series B | $35.0M | $308.3M | 2017 |
| Acuity Epirus Llc | — | Other | Series A | $4.2M | $38.8M | 2022 |
| Acuity Nylas LLC | — | Business Services | Seed | $3.0M | $48.2M | 2021 |
| Acuity Tanium LLC | — | Other Technology | Seed | $2.2M | $45.8M | 2021 |
| Acuity DataStax LLC | — | Other Technology | Seed | $1.4M | $26.8M | 2021 |
| Acuity Turo Llc | — | Other | Seed | $1.4M | $14.0M | 2022 |
| Acuity Spv Vii Llc | — | Investment Vehicle | Seed | $1.2M | $12.1M | 2022 |
Robert Spiegel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Spiegel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.